Shopping Cart 0
Cart Subtotal
USD 0

Glaukos Corp (GKOS) - Product Pipeline Analysis, 2019 Update

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 1500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 2250

Details

Summary

Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos' iStent is used in conjunction with cataract surgery. Glauko's iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm's canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Glaukos Corp

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Glaukos Corp Company Overview

Glaukos Corp Company Snapshot

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview

Glaukos Corp-Pipeline Analysis Overview

Glaukos Corp-Key Facts

Glaukos Corp-Major Products and Services

Glaukos Corp Pipeline Products by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp Pipeline Products Overview

iDose Travoprost Intraocular Implant

iDose Travoprost Intraocular Implant Product Overview

iDose Travoprost Intraocular Implant Clinical Trial

IOP Sensor System

IOP Sensor System Product Overview

iStent Infinite

iStent Infinite Product Overview

iStent Infinite Clinical Trial

iStent SA

iStent SA Product Overview

iStent SA Clinical Trial

iStent Supra Suprachoroidal Micro-Bypass Stent

iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview

iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial

Glaukos Corp-Key Competitors

Glaukos Corp-Key Employees

Glaukos Corp-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Glaukos Corp, Recent Developments

Aug 07, 2019: Glaukos announces second quarter 2019 financial results

Jun 04, 2019: International study confirms significant, sustained IOP and medication reduction following standalone implantation of Glaukos' iStent inject in glaucoma patients with substantial disease burden

May 08, 2019: Glaukos announces first quarter 2019 financial results

May 01, 2019: Multiple Surgeons to present data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery

Apr 15, 2019: Prospective, randomized trial highlights 5-Year performance of 2 standalone glaukos iStents vs. Topical Prostaglandin in newly diagnosed glaucoma patients

Mar 15, 2019: Pivotal trial results for Glaukos' iStent inject published in leading ophthalmic journal

Mar 13, 2019: Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

Mar 12, 2019: International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent Implantation in Combination with Cataract Surgery

Feb 27, 2019: Glaukos announces fourth quarter and full year 2018 financial results

Dec 11, 2018: Glaukos iStent inject Implantation with concomitant cataract surgery provides sustained reduction in IOP and medication burden, according to new study

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Glaukos Corp Pipeline Products by Equipment Type

Glaukos Corp Pipeline Products by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview

Glaukos Corp Pipeline Products by Equipment Type

Glaukos Corp Pipeline Products by Indication

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp, Key Facts

Glaukos Corp, Major Products and Services

Glaukos Corp Number of Pipeline Products by Development Stage

Glaukos Corp Pipeline Products Summary by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp Ongoing Clinical Trials Summary

iDose Travoprost Intraocular Implant-Product Status

iDose Travoprost Intraocular Implant-Product Description

iDose Travoprost Intraocular Implant-A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients

iDose Travoprost Intraocular Implant-Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure

IOP Sensor System-Product Status

IOP Sensor System-Product Description

iStent Infinite-Product Status

iStent Infinite-Product Description

iStent Infinite-A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients

iStent SA-Product Status

iStent SA-Product Description

iStent SA-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B

iStent SA-A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject)

iStent SA-A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin

iStent SA-Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject

iStent SA-The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study

iStent SA-Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors

iStent SA-US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery

iStent Supra Suprachoroidal Micro-Bypass Stent-Product Status

iStent Supra Suprachoroidal Micro-Bypass Stent-Product Description

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery

Glaukos Corp, Key Employees

Glaukos Corp, Subsidiaries

Glossary

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Glaukos Corp, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

STAAR Surgical Company

IRIDEX Corporation (US)

Cyberonics Inc

Company Profile

Company Profile Title

Summary

Glaukos Corp (Glaukos) is an ophthalmic medical device company that research and develops micro technologies to improve glaucoma therapy. The company develops injectable micro-scale therapies to address the complete range of glaucoma disease states and progression. It provides products such as microstent devices to treat glaucoma such as iStent trabecular micro-bypass stent for the treatment of mild- tomoderate open-angle glaucoma. Glaukos' iStent is used in conjunction with cataract surgery. Glauko's iStent improves outflow by creating a patent bypass between the anterior chamber and Schlemm's canal. The company markets its products through a network of distributors in Germany, Italy, Canada, Portugal, Spain, the UK and France, among others. Glaukos is headquartered in San Clemente, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

- The report analyzes all pipeline products in development for the company Glaukos Corp

- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

- The report provides detailed description of products in development, technical specification and functions

- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

- To formulate effective Research & Development strategies

- Develop market-entry and market expansion strategies

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Glaukos Corp Company Overview

Glaukos Corp Company Snapshot

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview

Glaukos Corp-Pipeline Analysis Overview

Glaukos Corp-Key Facts

Glaukos Corp-Major Products and Services

Glaukos Corp Pipeline Products by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp Pipeline Products Overview

iDose Travoprost Intraocular Implant

iDose Travoprost Intraocular Implant Product Overview

iDose Travoprost Intraocular Implant Clinical Trial

IOP Sensor System

IOP Sensor System Product Overview

iStent Infinite

iStent Infinite Product Overview

iStent Infinite Clinical Trial

iStent SA

iStent SA Product Overview

iStent SA Clinical Trial

iStent Supra Suprachoroidal Micro-Bypass Stent

iStent Supra Suprachoroidal Micro-Bypass Stent Product Overview

iStent Supra Suprachoroidal Micro-Bypass Stent Clinical Trial

Glaukos Corp-Key Competitors

Glaukos Corp-Key Employees

Glaukos Corp-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Recent Developments

Glaukos Corp, Recent Developments

Aug 07, 2019: Glaukos announces second quarter 2019 financial results

Jun 04, 2019: International study confirms significant, sustained IOP and medication reduction following standalone implantation of Glaukos' iStent inject in glaucoma patients with substantial disease burden

May 08, 2019: Glaukos announces first quarter 2019 financial results

May 01, 2019: Multiple Surgeons to present data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery

Apr 15, 2019: Prospective, randomized trial highlights 5-Year performance of 2 standalone glaukos iStents vs. Topical Prostaglandin in newly diagnosed glaucoma patients

Mar 15, 2019: Pivotal trial results for Glaukos' iStent inject published in leading ophthalmic journal

Mar 13, 2019: Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

Mar 12, 2019: International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent Implantation in Combination with Cataract Surgery

Feb 27, 2019: Glaukos announces fourth quarter and full year 2018 financial results

Dec 11, 2018: Glaukos iStent inject Implantation with concomitant cataract surgery provides sustained reduction in IOP and medication burden, according to new study

Appendix

Methodology

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Glaukos Corp Pipeline Products by Equipment Type

Glaukos Corp Pipeline Products by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status


List Of Table

List of Tables

Glaukos Corp Pipeline Products and Ongoing Clinical Trials Overview

Glaukos Corp Pipeline Products by Equipment Type

Glaukos Corp Pipeline Products by Indication

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp, Key Facts

Glaukos Corp, Major Products and Services

Glaukos Corp Number of Pipeline Products by Development Stage

Glaukos Corp Pipeline Products Summary by Development Stage

Glaukos Corp Ongoing Clinical Trials by Trial Status

Glaukos Corp Ongoing Clinical Trials Summary

iDose Travoprost Intraocular Implant-Product Status

iDose Travoprost Intraocular Implant-Product Description

iDose Travoprost Intraocular Implant-A Prospective, Randomized, Phase III IND Study of iDose Travoprost in Open-angle Glaucoma Patients

iDose Travoprost Intraocular Implant-Assessment of iDose Delivery System's Safety and Preliminary Efficacy for the Reduction of Elevated Intraocular Pressure

IOP Sensor System-Product Status

IOP Sensor System-Product Description

iStent Infinite-Product Status

iStent Infinite-Product Description

iStent Infinite-A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of iStent Infinite in Refractory Glaucoma Patients

iStent SA-Product Status

iStent SA-Product Description

iStent SA-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B

iStent SA-A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject)

iStent SA-A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated with Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin

iStent SA-Initial Phase of U.S. IDE Clinical Trial for Standalone Version of iStent inject

iStent SA-The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients with Glaucoma or Ocular Hypertension: An Observational Study

iStent SA-Trabeculectomy with MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors

iStent SA-US Investigational Device Exemption (IDE) Pivotal Study of iStent SA Standalone Micro-Invasive Glaucoma Surgery

iStent Supra Suprachoroidal Micro-Bypass Stent-Product Status

iStent Supra Suprachoroidal Micro-Bypass Stent-Product Description

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Second Generationtrabecular Micro-bypass Stents and One Suprachoroidal Stent a Multicenter Study According to Mpg 23.B

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects Treated with Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Mild to Moderate Open-angle Glaucoma Subjects with Cataract Treated with Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective Evaluation of Open-angle Glaucoma Subjects with One Prior Trabeculectomy Treated Concurrently with One Suprachoroidal Stent and Two Trabecular Micro-bypass Stents and a Postoperative Prostaglandin

iStent Supra Suprachoroidal Micro-Bypass Stent-A Prospective, Randomized, Single-masked, Controlled, Parallel Groups, Multicenter Clinical Investigation of the Glaukos Suprachoroidal Stent Model G3 in Conjunction with Cataract Surgery

Glaukos Corp, Key Employees

Glaukos Corp, Subsidiaries

Glossary

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Glaukos Corp, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies


Companies

STAAR Surgical Company

IRIDEX Corporation (US)

Cyberonics Inc